- ￥1480
- EK-Bioscience
- 国内
- SY4542
- 2025年07月13日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 英文名：
MKN45
- 库存：
1x10^6/瓶
- 供应商：
上海酶研
- 肿瘤类型：
胃癌
- 细胞类型：
MKN45
- 品系：
MKN45
- 组织来源：
人胃癌细胞
- 相关疾病：
详询
- 物种来源：
人
- 免疫类型：
详询
- 细胞形态：
贴壁/悬浮
- 是否是肿瘤细胞：
是
- 器官来源：
人胃癌细胞
- 运输方式：
顺丰快递
- 年限：
5年
- 生长状态：
生长良好
MKN45、MKN-45、MKN45细胞、MKN-45细胞、MKN45人胃癌细胞
Cell line name MKN45
Synonyms MKN-45; MKN 45
Accession CVCL_0434
Resource Identification Initiative To cite this cell line use: MKN45 (RRID:CVCL_0434)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: JFCR39 cancer cell line panel.
Part of: JFCR45 cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Population: Japanese.
Characteristics: MET-amplified, contains 12-13 copies of the gene (PubMed=29435981).
Doubling time: 30-33 hours (PubMed=3962675); 33 hours (PubMed=29435981); 30-38 hours (CelloPub=CLPUB00584); 16 hours (PubMed=2105279); ~60 hours (DSMZ=ACC-409).
Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Caution: Was indicated not to have a TP53 mutation in PubMed=1370612 and PubMed=15900046.
Misspelling: MKN46; Cosmic=968349.
Misspelling: MNK-45; Note=Occasionally.
Misspelling: MNK45; Note=Occasionally.
Misspelling: NKM-45; Note=Occasionally.
Misspelling: NKM45; Note=Occasionally.
Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
PubMed=9023415; DOI=10.1006/cimm.1996.1062
Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Cell. Immunol. 175:101-110(1997)
PubMed=9247707; DOI=10.1080/15216549700202901
Hatakeyama S., Gao Y.-H., Ohara-Nemoto Y., Kataoka H., Satoh M.
Expression of bone morphogenetic proteins of human neoplastic epithelial cells.
Biochem. Mol. Biol. Int. 42:497-505(1997)
PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)
PubMed=9665481; DOI=10.1016/S0002-9440(10)65561-7; PMCID=PMC1852940
Paciucci R., Vila M.R., Adell T., Diaz V.M., Tora M., Nakamura T., Real F.X.
Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.
Am. J. Pathol. 153:201-212(1998)
PubMed=11107048; DOI=10.1046/j.1440-1827.2000.01117.x
Yokozaki H.
Molecular characteristics of eight gastric cancer cell lines established in Japan.
Pathol. Int. 50:767-777(2000)
PubMed=11314020; DOI=10.1038/sj.onc.1204160
Kataoka H., Miura Y., Joh T., Seno K., Tada T., Tamaoki T., Nakabayashi H., Kawaguchi M., Asai K., Kato T., Itoh M.
Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1.
Oncogene 20:869-873(2001)
PubMed=11668190; DOI=10.1177/002215540104901105
Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.
Immunocytochemical analysis of cell lines derived from solid tumors.
J. Histochem. Cytochem. 49:1369-1378(2001)
PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x; PMCID=PMC11160020
Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H., Okanoue T., Inazawa J.
Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization.
Cancer Sci. 96:100-110(2005)
PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234
Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol. Cancer Ther. 4:399-412(2005)
PubMed=15900046; DOI=10.1093/jnci/dji133
Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.
J. Natl. Cancer Inst. 97:765-777(2005)
PubMed=15901131; DOI=10.1016/j.prp.2005.01.002
Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.
Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines.
Pathol. Res. Pract. 201:109-115(2005)
PubMed=18804159; DOI=10.1016/j.ygeno.2008.08.002
Jung J.-J., Jeung H.-C., Chung H.C., Lee J.O., Kim T.S., Kim Y.T., Noh S.H., Rha S.Y.
In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer.
Genomics 93:52-61(2009)
PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验*发表【中文论文】请标注：由上海酶研生物科技有限公司提供；
*发表【英文论文】请标注：From Shanghai EK-Bioscience Biotechnology Co., Ltd.
所需的时间就比夏天要长的多。SGC-7901胃癌细胞的消化传代大致步骤同上，但胰酶作用的时候应放在培养箱中，夏天0.1%的胰酶消化2分钟左右就够了，但冬天差不多要8分钟左右MDA-MB-231乳腺癌细胞消化传代基本同MKN-28，只是消化时间可稍长一点，1分钟左右。
本人养胃癌细胞sgc-7901已经半年多了，这半年来，可以说是及其不顺，同门的师哥师姐都说这个细胞很好养，增殖快，传代快，生命力旺盛，不容易感染，然，到我这里似乎就不像他们说的那样，问题接二连三的出现，但我从这一连串的失败中从一个懵懂无知者变成一个动作娴熟的能手，说句实在话还得感谢这批细胞给我带来的宝贵经验。首先我要说一点：无菌操作刚一接手细胞时，无菌相关事项早已耳熟能详，但我的第一批细胞在传第二代时不幸夭折，不明原因，总结一下还应该是操作的问题，被感染，虽没做细菌培养，但还应该是被感染致死
兰州大学第一医院李汛团队首次揭示胃癌演进中mRNA乙酰化修饰新机制
-acetylated COL5A1 研究论文。 图片来源：Springer Nature 官网 该项研究系统阐释了 NAT10 介导的 mRNA 乙酰化修饰促进胃癌细胞上皮 — 间质转化 (EMT) 和转移的机制作用，为通过靶向干预 NAT10 和 ac4C 通路抑制肿瘤演进提供新的策略。 这是国际上关于 mRNA 乙酰化修饰参与癌症进展的机制方面的首个研究成果。 图 1. 本文的科学示意图 研究中，团队成员首先发现 NAT10 在胃癌中表达广泛上调；NAT10 上调与患者预后不良及淋巴结转移密切相关。进一步
技术资料